 |
Photo courtesy of Yonhap News |
[Alpha Biz= Kim Sang Jin] Novo Holdings, the parent company of Novo Nordisk, is set to invest approximately KRW 100 billion in South Korea’s biohealth sector.
According to investment banking sources on the 27th, Novo Holdings will commit capital to a KRW 1.1 trillion blind fund being raised by Premier Partners. This marks the firm’s first participation in a domestic private equity fund in Korea.
Novo Holdings, wholly owned by the Novo Nordisk Foundation, manages assets worth around KRW 161 trillion as of end-2025 and is the largest shareholder of Novo Nordisk, known for its obesity treatment Wegovy.
The firm expressed a positive outlook on Korea’s biotech market. Amit Kakar, Head of Asia, said, “Korea has a well-established healthcare and life sciences ecosystem and stands out in Asia in terms of technological competitiveness.”
Premier Partners is known for its strong track record in biohealth investments, with portfolio companies including Medit, Vaim, ImmuneOncia, and Fraser Therapeutics. It also established a dedicated biotech investment team in 2016.
알파경제 김상진 대표기자(ceo@alphabiz.co.kr)
